WO2006003179A3 - Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use - Google Patents

Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use Download PDF

Info

Publication number
WO2006003179A3
WO2006003179A3 PCT/EP2005/053122 EP2005053122W WO2006003179A3 WO 2006003179 A3 WO2006003179 A3 WO 2006003179A3 EP 2005053122 W EP2005053122 W EP 2005053122W WO 2006003179 A3 WO2006003179 A3 WO 2006003179A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
kir2ds4
therapeutic use
antibodies binding
cytotoxicity
Prior art date
Application number
PCT/EP2005/053122
Other languages
French (fr)
Other versions
WO2006003179A2 (en
Inventor
Alessandro Moretta
Chiesa Mariella Della
Pascale Andre
Laurent Gauthier
Francois Romagne
Peter Andreas Nicolai Wagtmann
Ivan Svendsen
Stefan Zahn
Anders Svensson
Matthias Thorolfsson
Original Assignee
Novo Nordisk As
Innate Pharma
Univ Genova
Alessandro Moretta
Chiesa Mariella Della
Pascale Andre
Laurent Gauthier
Francois Romagne
Peter Andreas Nicolai Wagtmann
Ivan Svendsen
Stefan Zahn
Anders Svensson
Matthias Thorolfsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2004/000470 external-priority patent/WO2005003168A2/en
Priority to MX2007000210A priority Critical patent/MX2007000210A/en
Priority to CN200580022633.1A priority patent/CN1997670B/en
Priority to EP05758642A priority patent/EP1791868B1/en
Priority to JP2007518617A priority patent/JP5112863B2/en
Priority to DK05758642.2T priority patent/DK1791868T3/en
Priority to AT05758642T priority patent/ATE499386T1/en
Priority to CA2601417A priority patent/CA2601417C/en
Priority to KR1020077000069A priority patent/KR101299167B1/en
Priority to PL10178924T priority patent/PL2287195T3/en
Priority to EP10178924.6A priority patent/EP2287195B1/en
Priority to ES05758642T priority patent/ES2360467T3/en
Priority to BRPI0512911-7A priority patent/BRPI0512911B1/en
Priority to DE602005026538T priority patent/DE602005026538D1/en
Priority to AU2005259221A priority patent/AU2005259221B2/en
Application filed by Novo Nordisk As, Innate Pharma, Univ Genova, Alessandro Moretta, Chiesa Mariella Della, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson filed Critical Novo Nordisk As
Publication of WO2006003179A2 publication Critical patent/WO2006003179A2/en
Publication of WO2006003179A3 publication Critical patent/WO2006003179A3/en
Priority to IL179635A priority patent/IL179635A0/en
Priority to ZA2007/00736A priority patent/ZA200700736B/en
Priority to NO20070585A priority patent/NO341198B1/en
Priority to US12/244,170 priority patent/US8119775B2/en
Priority to US13/347,832 priority patent/US8614307B2/en
Priority to US13/936,486 priority patent/US8981065B2/en
Priority to US14/659,045 priority patent/US20150191547A1/en
Priority to US14/829,170 priority patent/US20150344576A1/en
Priority to NO20171133A priority patent/NO344566B1/en
Priority to CY20191100871T priority patent/CY1122391T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods for regulating an immune response in a subject are de­scribed. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1­4F1. Described also are also fragments and derivatives of such antibodies, as well as phar­maceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
PCT/EP2005/053122 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use WO2006003179A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CN200580022633.1A CN1997670B (en) 2004-07-01 2005-07-01 Human anti-KIR antibodies
AU2005259221A AU2005259221B2 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
DE602005026538T DE602005026538D1 (en) 2004-07-01 2005-07-01 TO THE RECEPTORS KIR2DL1, -2, -3, BUT NOT KIR2DS4, BINDING ANTIBODIES AND THEIR THERAPEUTIC USE
JP2007518617A JP5112863B2 (en) 2004-07-01 2005-07-01 Human anti-KIR antibody
DK05758642.2T DK1791868T3 (en) 2004-07-01 2005-07-01 Antibodies that bind to receptors KIR2DL1, -2, 3 but not KIR2DS4, as well as therapeutic use
AT05758642T ATE499386T1 (en) 2004-07-01 2005-07-01 ANTIBODIES BINDING TO THE RECEPTORS KIR2DL1, -2, -3, BUT NOT KIR2DS4, AND THEIR THERAPEUTIC USE
CA2601417A CA2601417C (en) 2004-07-01 2005-07-01 Human anti-kir antibodies
KR1020077000069A KR101299167B1 (en) 2004-07-01 2005-07-01 Human anti-kir antibodies
PL10178924T PL2287195T3 (en) 2004-07-01 2005-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
EP10178924.6A EP2287195B1 (en) 2004-07-01 2005-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
ES05758642T ES2360467T3 (en) 2004-07-01 2005-07-01 ANTIBODIES THAT JOIN KIR2DL1, -2, -3 RECEPTORS BUT NOT KIR2DS4 AND THERAPEUTIC USE.
BRPI0512911-7A BRPI0512911B1 (en) 2004-07-01 2005-07-01 ISOLATED HUMAN ANTIBODY, NUCLEIC ACID, VECTOR, CELL, METHOD OF PRODUCING A HUMAN ANTI-KIR ANTIBODY, PHARMACEUTICAL COMPOSITION, AND METHOD OF ENHANCED NK CELL ACTIVITY IN A PATIENT IN NEED OF THE SAME
EP05758642A EP1791868B1 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
MX2007000210A MX2007000210A (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use.
IL179635A IL179635A0 (en) 2004-07-01 2006-11-27 Human anti-kir antibodies
ZA2007/00736A ZA200700736B (en) 2004-07-01 2007-01-26 Human anti-kir antibodies
NO20070585A NO341198B1 (en) 2004-07-01 2007-01-31 Human anti-KIR antibody.
US12/244,170 US8119775B2 (en) 2004-07-01 2008-10-02 Human anti-KIR antibodies
US13/347,832 US8614307B2 (en) 2004-07-01 2012-01-11 Nucleic acids encoding human anti-kir antibodies
US13/936,486 US8981065B2 (en) 2004-07-01 2013-07-08 Human anti-KIR antibodies
US14/659,045 US20150191547A1 (en) 2004-07-01 2015-03-16 Human anti-kir antibodies
US14/829,170 US20150344576A1 (en) 2004-07-01 2015-08-18 Human anti-kir antibodies
NO20171133A NO344566B1 (en) 2004-07-01 2017-07-07 Isolated antibody or fragment thereof, nucleic acid encoding said antibody or antibody fragment, vector comprising the nucleic acid, cell comprising the vector or hybridoma expressing the antibody or antibody fragment, method of making antibody or antibody fragment, pharmaceutical composition comprising said antibody fragment or method production of antibody.
CY20191100871T CY1122391T1 (en) 2004-07-01 2019-08-13 PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPCT/DK2004/000470 2004-07-01
PCT/DK2004/000470 WO2005003168A2 (en) 2003-07-02 2004-07-01 Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
IBPCT/IB2004/002464 2004-07-01
PCT/IB2004/002464 WO2005003172A2 (en) 2003-07-02 2004-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
DKPA200500025 2005-01-06
DKPA200500025 2005-01-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11630176 A-371-Of-International 2005-07-01
US12/244,170 Continuation US8119775B2 (en) 2004-07-01 2008-10-02 Human anti-KIR antibodies

Publications (2)

Publication Number Publication Date
WO2006003179A2 WO2006003179A2 (en) 2006-01-12
WO2006003179A3 true WO2006003179A3 (en) 2006-05-26

Family

ID=35431942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/053122 WO2006003179A2 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use

Country Status (10)

Country Link
US (5) US8119775B2 (en)
EP (2) EP1791868B1 (en)
JP (1) JP5112863B2 (en)
CN (1) CN1997670B (en)
AU (1) AU2005259221B2 (en)
CA (1) CA2601417C (en)
DK (1) DK2287195T3 (en)
PL (1) PL2287195T3 (en)
SI (1) SI2287195T1 (en)
WO (1) WO2006003179A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844760B2 (en) 2015-05-06 2023-12-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
KR101444717B1 (en) 2003-07-02 2014-09-26 노보 노르디스크 에이/에스 Compositions and methods for regulating nk cell activity
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
DE602005026538D1 (en) * 2004-07-01 2011-04-07 Innate Pharma TO THE RECEPTORS KIR2DL1, -2, -3, BUT NOT KIR2DS4, BINDING ANTIBODIES AND THEIR THERAPEUTIC USE
CA2572938C (en) 2004-07-10 2019-10-15 Fox Chase Cancer Center Genetically modified human natural killer cell lines
EP1809738B1 (en) * 2004-11-02 2014-03-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for treating hyperproliferative disorders
JP5855326B2 (en) * 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス Anti-KIR combination therapy and method
ATE531733T1 (en) 2005-01-06 2011-11-15 Novo Nordisk As KIR-BINDING ACTIVE INGREDIENTS AND METHODS FOR THEIR USE
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
BRPI0708909B8 (en) 2006-03-15 2021-05-25 Alexion Pharma Inc use of an antibody that binds to c5 to treat a patient suffering from paroxysmal nocturnal hemoglobinuria
AU2013237638B2 (en) * 2007-01-11 2016-10-13 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
ES2627923T3 (en) * 2007-01-11 2017-08-01 Novo Nordisk A/S Anti-KIR antibodies, formulations and uses thereof
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
EP2494062B1 (en) * 2009-10-28 2016-12-28 Janssen Biotech, Inc. Anti-glp-1r antibodies and their uses
WO2012047985A1 (en) * 2010-10-06 2012-04-12 St. Jude Children's Research Hospital Molecular determinant-based typing of kir alleles and kir-ligands
TWI664191B (en) * 2010-11-22 2019-07-01 天賜製藥公司 Nk cell modulating treatments and methods for treatment of hematological malignancies
KR102046666B1 (en) * 2011-05-25 2019-11-19 이나뜨 파르마 Anti-kir antibodies for the treatment of inflammatory disorders
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
CN102617707B (en) * 2011-09-19 2014-01-29 江苏师范大学 Preparation method of new homologue 2-methyl-actinomycin D of actinomycin D
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
KR102037541B1 (en) 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Polypeptide constructs and uses thereof
BR112015007184A2 (en) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CA2899241C (en) 2013-02-20 2023-03-28 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
RU2015147696A (en) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. METHODS FOR TREATING A MALIGNANT TUMOR
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
FI3677591T3 (en) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
RU2016107426A (en) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. COMBINING CD27 AGONISTS AND INHIBITING IMMUNE CONTROL POINTS TO STIMULATE IMMUNITY
DK3030262T3 (en) 2013-08-08 2019-12-02 Cytune Pharma COMBINED PHARMACEUTICAL COMPOSITION
AU2014304931B2 (en) 2013-08-08 2018-05-10 Assistance Publique - Hopitaux De Paris IL-15 and IL-15Raplha sushi domain based modulokines
ES2707057T3 (en) * 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
AU2015243246B2 (en) * 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
MX2016013559A (en) * 2014-04-16 2017-04-27 Biocon Ltd Stable protein formulations comprising a molar excess of sorbitol.
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
JP6654781B2 (en) * 2014-08-29 2020-02-26 国立大学法人北海道大学 Monoclonal antibody against KIR2DS1
EP3212227B1 (en) 2014-10-28 2020-01-15 Children's University Hospital Tübingen Treatment of pediatric bcp-all patients with an anti-kir antibody
UA125637C2 (en) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд INTERFERON α2b VARIANTS
WO2016070001A1 (en) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
CN105669862A (en) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 Anti-human PD-L1/KIR bispecific antibody, preparation method and application thereof
CN114891816A (en) 2015-02-06 2022-08-12 新加坡国立大学 Nucleic acid, engineering immune cell containing nucleic acid, preparation method and application of nucleic acid
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
SI3283107T1 (en) 2015-04-17 2020-10-30 Bristol-Myers Squibb Company Compositions comprising a combination of ipilimumab and nivolumab
US20180140572A1 (en) 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
USD771281S1 (en) * 2015-07-03 2016-11-08 Arktura Llc Architectural fixture
USD777951S1 (en) * 2015-07-03 2017-01-31 Arktura, Llc Architectural fixture
USD785212S1 (en) * 2015-07-03 2017-04-25 Arktura Llc Architectural fixture
USD784565S1 (en) * 2015-07-03 2017-04-18 Arktura Llc Architectural fixture
CN116196426A (en) 2015-07-16 2023-06-02 百欧肯治疗有限公司 Compositions and methods for treating cancer
CA2990520C (en) 2015-07-24 2023-06-27 Innate Pharma Methods for detecting tissue infiltrating nk cells
CN108884159A (en) 2015-11-07 2018-11-23 茂体外尔公司 The composition use for cancer treatment blocked comprising tumor suppressor gene treatment and immunologic test point
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
CA3010779A1 (en) 2016-03-16 2017-09-21 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
BR112018073781A2 (en) 2016-05-20 2019-02-26 Biohaven Pharmaceutical Holding Company Ltd. use of immunotherapeutic glutamate modulating agents for cancer treatment
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
CN110267651B (en) 2016-09-27 2023-09-01 得克萨斯系统大学评议会 Methods of enhancing immune checkpoint blocking therapies by modulating microbiome
JP7041136B2 (en) 2016-10-12 2022-03-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Methods and Compositions for TUSC2 Immunotherapy
KR20190068602A (en) 2016-10-21 2019-06-18 이나뜨 파르마 Treatment with anti-KIR3DL2 agonists
SG11201903830TA (en) 2016-11-22 2019-05-30 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020510624A (en) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド Methods and compositions comprising viral gene therapy and immune checkpoint inhibitors for the treatment and prevention of cancer and infectious diseases
CA3052291A1 (en) * 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
KR20190133213A (en) 2017-03-31 2019-12-02 브리스톨-마이어스 스큅 컴퍼니 How to treat a tumor
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
BR112019025352A8 (en) 2017-05-29 2023-05-02 Inst Nat Sante Rech Med CANCER-ASSOCIATED IMMUNOSUPPRESSION INHIBITORS
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Methods of treating tumor
JP2021518408A (en) 2018-03-19 2021-08-02 マルチビア インコーポレイテッド Methods and Compositions Containing Tumor Suppressor Gene Therapies and CD122 / CD132 Agonists for Cancer Treatment
BR112020018539A2 (en) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company ANTIBODIES AGAINST MICA AND / OR MICB AND USES OF THE SAME
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3773685A1 (en) 2018-03-25 2021-02-17 SNIPR Biome ApS. Treating & preventing microbial infections
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN109125247A (en) * 2018-09-06 2019-01-04 广州苿莱生物科技有限公司 The preparation method of adult stem cell freeze-dried powder and its application in cosmetics
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
JP2022534982A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Cellular localization signatures and their uses
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN115768885A (en) 2020-06-03 2023-03-07 Mv生物治疗股份有限公司 Combinations of ATP hydrolase and immune checkpoint modulators and uses thereof
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
KR20230116767A (en) * 2020-07-16 2023-08-04 다나-파버 캔서 인스티튜트 인크. Antibodies to MUC1-C/Extracellular Domain (MUC1-C/ECD)
CN116438199A (en) 2020-08-31 2023-07-14 百时美施贵宝公司 Cell localization features and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
MX2023007734A (en) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Antibody compositions and methods of use thereof.
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024089418A1 (en) 2022-10-24 2024-05-02 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
WO2024090458A1 (en) * 2022-10-25 2024-05-02 第一三共株式会社 Method for avoiding immune rejection using agonist for inhibitory kir

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026671A1 (en) * 1998-10-29 2000-05-11 Connex Gmbh Detection of acid-resistant micro-organisms in a stool

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH0515592A (en) 1991-07-05 1993-01-26 Morishita Roussel Kk Method, device and appliance for administering flowable nutriments dropwise
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH05112863A (en) 1991-10-21 1993-05-07 Nippon Steel Corp Formation of thin film
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU4541093A (en) 1992-06-18 1994-01-24 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
PT804070E (en) 1993-03-09 2000-11-30 Genzyme Corp ISOLATION OF COMPONENTS OF INTEREST FROM MILK.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5808028A (en) * 1994-05-24 1998-09-15 The United States Of America As Represented By The Department Of Health And Human Services Molecular clone of a P58 receptor protein and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JPH11503914A (en) 1995-04-21 1999-04-06 セル ジェネシス，インコーポレイテッド Generation of large genomic DNA deletions
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
DK0942968T3 (en) 1996-12-03 2008-06-23 Amgen Fremont Inc Fully human antibodies that bind EGFR
CA2322749A1 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
DE69942037D1 (en) 1998-12-23 2010-04-01 Amgen Fremont Inc HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
KR100419555B1 (en) * 2000-05-29 2004-02-19 주식회사유한양행 A variable region of the monoclonal antibody against a s-surface antigen of hepatitis b virus and a gene encoding the same
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
CA2450019A1 (en) 2001-06-08 2002-12-19 Icon Genetics, Inc. Production of proteins in plants
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
BR0307216A (en) 2002-01-28 2005-12-20 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen (psma)
KR101444717B1 (en) 2003-07-02 2014-09-26 노보 노르디스크 에이/에스 Compositions and methods for regulating nk cell activity
CN104645327A (en) * 2003-07-24 2015-05-27 依奈特制药公司 Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
KR20050111185A (en) * 2004-05-21 2005-11-24 삼성에스디아이 주식회사 Plasma display panel
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
WO2006072624A2 (en) * 2005-01-06 2006-07-13 Novo Nordisk A/S Compositions and methods for treating viral infection
ATE531733T1 (en) * 2005-01-06 2011-11-15 Novo Nordisk As KIR-BINDING ACTIVE INGREDIENTS AND METHODS FOR THEIR USE
US8709411B2 (en) * 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
KR102046666B1 (en) * 2011-05-25 2019-11-19 이나뜨 파르마 Anti-kir antibodies for the treatment of inflammatory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026671A1 (en) * 1998-10-29 2000-05-11 Connex Gmbh Detection of acid-resistant micro-organisms in a stool

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BARTEN R ET AL: "Divergent and convergent evolution of NK-cell receptors", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 22, no. 1, 1 January 2001 (2001-01-01), pages 52 - 57, XP004255853, ISSN: 1471-4906 *
DATABASE Geneseq [online] 22 April 2003 (2003-04-22), "Mouse antibody 3E11 light chain variable region.", XP002309299, retrieved from EBI accession no. GSN:ABG74248 Database accession no. ABG74248 *
FARAG SHERIF S ET AL: "Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect", BLOOD, vol. 100, no. 6, 15 September 2002 (2002-09-15), pages 1935 - 1947, XP002308880, ISSN: 0006-4971 *
KOH CRYSTAL Y ET AL: "NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution.", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION : JOURNAL OF THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION. 2002, vol. 8, no. 1, 2002, pages 17 - 25, XP002308879, ISSN: 1083-8791 *
MORETTA ALESSANDRO ET AL: "Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis", ANNUAL REVIEW OF IMMUNOLOGY ANNUAL REVIEWS {A}, 4139 EL CAMINO WAY, PALO ALTO, CA, 94303-0139, USA SERIES : ANNUAL REVIEW OF IMMUNOLOGY (ISSN 0732-0582), 2001, pages 197 - 223, XP008016880, ISSN: 0-8243-3019-6 *
MORETTA ALESSANDRO ET AL: "Receptors for HLA class-I molecules in human natural killer cells", ANNUAL REVIEW OF IMMUNOLOGY ANNUAL REVIEWS INC. {A}, P.O. BOX 10139, 4139 EL CAMINO WAY, PALO ALTO, CALIFORNIA 94306, USA SERIES : ANNUAL REVIEW OF IMMUNOLOGY (ISSN 0732-0582), 1996, pages 619 - 648, XP002308882, ISSN: 0-8243-3014-5 *
POGGI A ET AL: "P40, A NOVEL SURFACE MOLECULE INVOLVED IN THE REGULATION OF THE NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED CYTOLYTIC ACTIVITY IN HUMANS", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 25, no. 2, 1995, pages 369 - 376, XP009041151, ISSN: 0014-2980 *
SHIN JEON-SOO ET AL: "Monoclonal antibodies with various reactivity to p58 killer inhibitory receptors", HYBRIDOMA, vol. 18, no. 6, December 1999 (1999-12-01), pages 521 - 527, XP001041418, ISSN: 0272-457X *
SPAGGIARI GRAZIA MARIA ET AL: "Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.", BLOOD, vol. 100, no. 12, 1 December 2002 (2002-12-01), pages 4098 - 4107, XP002308878, ISSN: 0006-4971 *
WARREN H S ET AL: "Functional analysis of CD158b monoclonal antibodies recognizing the killer Ig-like receptors KIR2DS2, KIR2DL2 and KIR2DL3", TISSUE ANTIGENS, vol. 55, no. Supplement 1, 2000, & 7TH WORKSHOP AND CONFERENCE ON HUMAN LEUCOCYTE DIFFERENTIATION ANTIGENS; HARROGATE, ENGLAND, UK; JUNE 20-24, 2000, pages 80 - 81, XP009040899, ISSN: 0001-2815 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844760B2 (en) 2015-05-06 2023-12-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota

Also Published As

Publication number Publication date
CA2601417C (en) 2018-10-30
EP1791868A2 (en) 2007-06-06
AU2005259221A1 (en) 2006-01-12
CN1997670A (en) 2007-07-11
EP2287195A2 (en) 2011-02-23
US8614307B2 (en) 2013-12-24
JP5112863B2 (en) 2013-01-09
PL2287195T3 (en) 2019-10-31
US20150344576A1 (en) 2015-12-03
CN1997670B (en) 2014-04-30
JP2008506368A (en) 2008-03-06
US20130287770A1 (en) 2013-10-31
US20150191547A1 (en) 2015-07-09
EP2287195B1 (en) 2019-05-15
US8119775B2 (en) 2012-02-21
EP1791868B1 (en) 2011-02-23
EP2287195A3 (en) 2013-12-04
US20120208237A1 (en) 2012-08-16
DK2287195T3 (en) 2019-08-19
WO2006003179A2 (en) 2006-01-12
US20090081240A1 (en) 2009-03-26
CA2601417A1 (en) 2006-01-12
US8981065B2 (en) 2015-03-17
SI2287195T1 (en) 2019-08-30
AU2005259221B2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2006003179A3 (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
WO2005003172A3 (en) Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
IL161686A (en) Use of a soluble monoclonal antibody that specifically binds trail receptor dr5 in the manufacture of pharmaceutical compositions targeting cells expressing dr5
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2007009064A3 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
MX2022008582A (en) Anti-trem2 antibodies and methods of use thereof.
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
WO2005058815A3 (en) Ip-10 antibodies and their uses
PL377337A1 (en) Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
WO2005010151A3 (en) Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005097185A3 (en) Irta-5 antibodies and their uses
MX2021009722A (en) Anti-trem2 antibodies and methods of use thereof.
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
BRPI0514124A (en) human monoclonal antibodies to human il-4
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2005108430A3 (en) Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
MX2007000210A (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use.
WO2017160699A3 (en) Method of preventing graft versus host disease
WO2023097219A3 (en) Anti-idiotype antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 179635

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 7162/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005259221

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007518617

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005758642

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005259221

Country of ref document: AU

Date of ref document: 20050701

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2601417

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2005259221

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077000069

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200580022633.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2007/000210

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007/00736

Country of ref document: ZA

Ref document number: 200700736

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006144820

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020077000069

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005758642

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512911

Country of ref document: BR